

## Certificate of Analysis

### Akt1/PKB $\alpha$ (S473D), active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-453, 14-453-K, 14-453M

Parent Lot # 1600485

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal 6His-tagged, recombinant human Akt1/PKB  $\alpha$  (S473D), residues 118–end containing the mutation S473D. Expressed by baculovirus in Sf21 insect cells. Purified using Ni<sup>2+</sup>/NTA agarose. Activated using PDK1 (cat# 14-452) and repurified using heparin Sepharose. Purity 97.2% by SDS-PAGE and Coomassie blue staining. MW = 45kDa.

**Specific Activity (Parent lot# 1600485):** 6080U/mg, where one unit of Akt1/PKB  $\alpha$  (S473D), active activity is defined as 1nmol phosphate incorporated into 30 $\mu$ M modified crosptide per minute at 30°C with a final ATP concentration of 100 $\mu$ M.

**Formulation:** 1.069mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 2.0–5.6ng of this lot of enzyme phosphorylated 30 $\mu$ M modified crosptide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed product identity as Akt1/PKB $\alpha$  (S473D) with the translated native sequence listed on page three.



**SDS-PAGE and Coomassie Stain:** Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 $\mu$ g of Akt1/PKB $\alpha$  (S473D), active.

## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Modified Crosstide:** Use at a final assay concentration of 30 $\mu$ M. Prepare a 300 $\mu$ M stock and add 2.5 $\mu$ l of stock per assay point.
3. **Akt1/PKB $\alpha$  (S473D), active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 0.1% 2-mercaptoethnaol, 1mg/ml BSA. Use 2.0–5.6ng per assay point.
4. **[ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[ $\gamma$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

#### Assay Procedure (96 well plate format):

1. Add 5 $\mu$ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 $\mu$ l of **modified crosstide**.
3. Add **2.5 $\mu$ l (2.0–5.6ng) Akt1/PKB $\alpha$  (S473D), active**.
4. Add 5 $\mu$ l of dH<sub>2</sub>O.
5. Add 10 $\mu$ l of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 $\mu$ l of 3% phosphoric acid.
8. Transfer a 10 $\mu$ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 $\mu$ l of 30% phosphoric acid.

## Certificate of Analysis

### Akt1/PKB alpha (S473D) Sequence Information

<b><u>Protein</u></b>	human Akt1 (118–end, S473D)
<b><u>Tags</u></b>	N-terminal 6His
<b><u>Native sequence</u></b>	M29 of the recombinant protein is equivalent to M118 of human Akt1
<b><u>Accession number</u></b>	GenBank M63167. S478G with regard to this accession, reported in EMBL BE206796. S473D conflict mimics phosphorylation of S473.

#### **Recombinant Akt1 amino acid sequence:**

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMGSMD FRSGSPSDNS GAEEMEVSLA KPKHRVTMNE
61 FEYLNKLLGKG TFGKVLVKE KATGRYYAMK ILKKEVIVAK DEVAHTLTEN RVLQNSRHPPF
121 LTALKYSFQT HDRLCFVMEY ANGGELFFHL SRERVFSEDR ARFYGAEIVS ALDYLNHSEKN
181 VVYRDLKLEN LMLDKDGHK ITDFGLCKEG IKDGATMKTG CGTPEYLAPL VLEDNDYGRA
241 VDWWGLGVVM YEMMCGRLPF YNQDHEKLF LILMEEIRFP RTLGPPEAKSL LSGLLKKDPK
301 QRLGGGSEDA KEIMQHRFFA GIVWQHVEK KLSPPFKPQV TSETDTRYFD EEFTAQMITI
361 TPPDQDSME CVDSERRPHF PQFDYSASGT A

```

#### **Recombinant Akt1 nucleotide sequence:**

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg ggcctatggg atccatggac ttccggtcgg gtcacccag tgacaactca
121 ggggctgaag agatggagggt gtccctggcc aagcccaagc accgcgtgac catgaacgag
181 tttgagtacc tgaagctgct gggcaagggc actttcggca aggtgatcct ggtgaaggag
241 aaggccacag gccgctacta cgccatgaag atcctcaaga aggaagtcat cgtggccaag
301 gacgagggtg cccacacact caccgagaac cgcgtcctgc agaactccag gcaccccttc
361 ctcacagccc tgaagtactc tttccagacc caccgaccgc tctgctttgt catggagtac
421 gccaacgggg gcgagctggt cttccacctg tcccgggagc gtgtgttctc cgaggaccgg
481 gcccgtctct atggcgctga gattgtgtca gccctggact acctgcactc ggagaagaac
541 gtggtgtacc gggacctcaa gctggagaac ctcatgctgg acaaggacgg gcacattaag
601 atcacagact tcgggctgtg caaggagggg atcaaggacg gtgccaccat gaagaccttt
661 tgcggcacac ctgagtacct ggcccccgag gtgctggagg acaatgacta cggccgtgca
721 gtggactggt gggggctggg cgtggtcatg tacgagatga tgtgcggtcg cctgcccttc
781 tacaaccagg accatgagaa gctttttgag ctcatcctca tggaggagat ccgcttcccg
841 cgcacgcttg gtcccagggc caagtccttg ctttcagggc tgctcaagaa ggaccccaag
901 cagaggcttg gcgggggctc cgaggacgcc aaggagatca tgcagcatcg cttctttgcc
961 ggtatcgtgt ggcagcacgt gtacgagaag aagctcagcc cacccttcaa gccccaggtc
1021 acgtcggaga ctgacaccag gtattttgat gaggagttca cggcccagat gatcaccatc
1081 acaccacctg accaagatga cagcatggag tgtgtggaca gcgagcgcag gccccacttc
1141 cccagttcg actactcggc cagcggcacg gcctga

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.